Literature DB >> 18683571

Effective bladder preservation strategy with low-dose radiation therapy and concurrent intraarterial chemotherapy for muscle-invasive bladder cancer.

Hitoshi Ikushima1, Seiji Iwamoto, Kyohsuke Osaki, Shunsuke Furutani, Kyoh Yamashita, Takashi Kawanaka, Akiko Kubo, Yoshihiro Takegawa, Takaharu Kudoh, Hiroomi Kanayama, Hiromu Nishitani.   

Abstract

PURPOSE: The aim of this study was to evaluate retrospectively the toxicity and response, bladder preservation, and survival of patients with muscle-invasive bladder cancer treated with multimodality therapy consisting of low-dose radiation therapy (RT) and concurrent intraarterial chemotherapy (IACT). METHODS AND MATERIALS: . Between November 1999 and July 2005, a total of 27 consecutive, previously untreated patients with muscle-invasive bladder cancer underwent transurethral bladder tumor resection followed by concurrent low-dose RT and IACT. Patients who achieved a complete response (CR) were followed up closely without further therapy, and patients who did not achieve a CR underwent further treatment.
RESULTS: Complete response was achieved in 22 of 27 patients (81%). Of these 22 patients, 7 developed recurrences, and 3 died of their disease. In five patients who did not achieve CR, one died from bone metastases. The 3-year overall survival rate was 81%, with a median follow-up time of 27 months; and 22 of 27 patients (81%) with a preserved bladder were tumor-free at the last follow-up. Three patients (11%) developed grade 3 acute hematological toxicity.
CONCLUSION: Multimodality therapy consisting of low-dose RT and concurrent IACT for muscle-invasive bladder cancer can achieve survival rates similar to those in patients treated with radical cystectomy, with successful bladder preservation and minimal adverse effects.

Entities:  

Mesh:

Year:  2008        PMID: 18683571     DOI: 10.1007/s11604-007-0211-x

Source DB:  PubMed          Journal:  Radiat Med        ISSN: 0288-2043


  30 in total

1.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

Authors:  J D Cox; J Stetz; T F Pajak
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

2.  A bladder preservation regimen using intra-arterial chemotherapy and radiotherapy for invasive bladder cancer: a prospective study.

Authors:  N Miyanaga; H Akaza; T Okumura; N Sekido; K Kawai; T Shimazui; K Kikuchi; K Uchida; H Takeshima; K Ohara; Y Akine; Y Ita
Journal:  Int J Urol       Date:  2000-02       Impact factor: 3.369

3.  Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis.

Authors:  M K Gospodarowicz; N V Hawkins; G A Rawlings; J G Connolly; M A Jewett; G M Thomas; J G Herman; P G Garrett; T Chua; W Duncan
Journal:  J Urol       Date:  1989-12       Impact factor: 7.450

Review 4.  Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy.

Authors:  A Trotti; R Byhardt; J Stetz; C Gwede; B Corn; K Fu; L Gunderson; B McCormick; M Morrisintegral; T Rich; W Shipley; W Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-04-01       Impact factor: 7.038

5.  Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy.

Authors:  Marcus L Quek; John P Stein; Peter W Nichols; Jie Cai; Gus Miranda; Susan Groshen; Siamak Daneshmand; Eila C Skinner; Donald G Skinner
Journal:  J Urol       Date:  2005-07       Impact factor: 7.450

6.  Effective bladder sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer.

Authors:  Libni Eapen; David Stewart; John Collins; Rebecca Peterson
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

7.  Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.

Authors:  W Tester; R Caplan; J Heaney; P Venner; R Whittington; R Byhardt; L True; W Shipley
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

8.  Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results.

Authors:  Claus Rödel; Gerhard G Grabenbauer; Reinhard Kühn; Thomas Papadopoulos; Jürgen Dunst; Martin Meyer; Karl M Schrott; Rolf Sauer
Journal:  J Clin Oncol       Date:  2002-07-15       Impact factor: 44.544

9.  RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.

Authors:  Michael P Hagan; Kathryn A Winter; Donald S Kaufman; Zev Wajsman; Anthony L Zietman; Naill M Heney; Leonard M Toonkel; Christopher U Jones; John D Roberts; William U Shipley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-11-01       Impact factor: 7.038

Review 10.  Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder.

Authors:  M D Michaelson; W U Shipley; N M Heney; A L Zietman; D S Kaufman
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

View more
  5 in total

Review 1.  [Follow-up of bladder cancer : The right examinations at the right time].

Authors:  P Olbert; P J Goebell; A Hegele
Journal:  Urologe A       Date:  2018-06       Impact factor: 0.639

2.  External beam radiation plus concurrent intra-arterial chemotherapy with low dose cisplatin for muscle invasive bladder cancer.

Authors:  Yoshihiro Matsumoto; Shoji Samma; Shinji Fukui; Yasushi Nakai; Yoriaki Kagebayashi; Kazumasa Torimoto
Journal:  Indian J Urol       Date:  2015 Jan-Mar

3.  KIF22 promotes bladder cancer progression by activating the expression of CDCA3.

Authors:  Kai Li; Song Li; Shuai Tang; Minghao Zhang; Zhen Ma; Qi Wang; Fangmin Chen
Journal:  Int J Mol Med       Date:  2021-10-11       Impact factor: 4.101

4.  Conservative treatment of invasive bladder cancer.

Authors:  N J Rene; F B Cury; L Souhami
Journal:  Curr Oncol       Date:  2009-08       Impact factor: 3.677

5.  Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis.

Authors:  Victor M Schuettfort; Benjamin Pradere; Fahad Quhal; Hadi Mostafaei; Ekaterina Laukhtina; Keiichiro Mori; Reza Sari Motlagh; Margit Fisch; David D'Andrea; Michael Rink; Paolo Gontero; Francesco Soria; Shahrokh F Shariat
Journal:  World J Urol       Date:  2020-09-29       Impact factor: 4.226

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.